Possible Next Steps

- Engage DOD groups in ongoing pilot/demo project (eMERGE, GMDP, etc); mechanisms to be explored
- Directed discussion with PCORI on expanding genomic medicine/genomic research projects
- Convene FDA/CMS/private payers to review and advise on GMDP and eMERGE demostartion projects with longer term goal of general principles
- Standards/IT/policy project
- Discussion needed on national strategy. First steps are to understand with greater detail the goals, resources, barriers, for each agency and how they play in the eco-system (consider T1-T4 framework).

Components of GM Implementation Strategies	UK	Canada	Italy	ESF	CAP	IOM	AMA
Service delivery infrastructure for requesting and receiving genomic results	X		X	X	X		
Provider- and patient friendly, model genomic interpretive test reports and patient consultations					X		
Bioinformatics infrastructure for relating clinical characteristics to variants	X	X	X	X	X	X	X
Data sharing in accessible research databases	X			X	X		X
Standardized phenotypic, patient, variant, and reference information	X			X	X	X	X
Assessment of health economics and cost-effectiveness	X	X	X		X	X	X
Evidence of clinical validity and utility	X	X	X	X	X	X	X
Consent model	X			X			X
Training/workforce development	X		X	X	X		
Ethical and legal framework to protect against potential abuses	X	X			X		X
Engaging public and building awareness	X	X	X	X			
Genomics-based risk stratification and communication		X	X				
Genetic test regulation or registration			X		X		X
Use of patented medical information and conflict of interest in medical innovation					X	X	X
Reimbursement for genomic testing, interpretations and consultations					X		X
Equitable access	X		X	X			X

Components of GM Implementation Strategies	AF	VA	CMS	FDA	AHRQ	ASH	PCORI	CDC
Service delivery infrastructure for requesting and receiving genomic results		X						
Provider- and patient friendly, model genomic interpretive test reports and patient consultations		X						
Bioinformatics infrastructure for relating clinical characteristics to variants	X	X		X	X			
Data sharing in accessible research databases					X	X		
Standardized phenotypic, patient, variant, and reference information	X	X		X				X
Assessment of health economics and cost-effectiveness			X		X			
Evidence of clinical validity and utility		X	X	X	X			X
Consent model	X					X		
Training/workforce development		X						
Ethical and legal framework to protect against potential abuses	X	X				X		
Engaging public and building awareness	X	X					X	
Genomics-based risk stratification and communication	X							X
Genetic test regulation or registration			X	X				
Use of patented medical information and conflict of interest in medical innovation								
Reimbursement for genomic testing, interpretations and consultations				X	X			
Equitable access	X	X	X		X	X	X	

The UK Human Genomics Strategy Group

- Monitor advances in genetic and genomics evaluate their benefit to healthcare services in the NHS

- Ensure successful translation of laboratory and academic research into quality care

- Develop infrastructure to enable access to high quality genomic and genetic testing services

- Develop the bioinformatics platform needed to underpin genomic and genetic testing

- Train the NHS and public health workforce

- Articulate the legal and ethical issues around the use of genomic data

- Raise public awareness of genomic technology and how it can be used to benefit the care of patients across the NHS

Is a National Strategy Possible?
The UK Has a Bold Vision

By 2020:

- *The NHS will be a world leader in the development and use of genomic technology in the areas of healthcare and public health*

- *Genomic information and clinical genetic testing will be used across the NHS*

- *Healthcare providers within the NHS will confidently use genomic information within their roles*

- *Effective public engagement will increase awareness of the role of genomic information in healthcare*

UK Genomic Medicine Report, January 2012

Possible Outcomes

- White paper describing needs within US and possible approaches for addressing them
- Commonalities in interests or opportunities across agencies as foundations for collaboration
- Initial use cases that all agencies largely agree upon
- Plans for communication and collaboration across agencies in moving genomic medicine forward
- Needs and goals for interaction with possible international efforts